Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

• ClinicalTrials.gov Identifier: NCT04853329
• Recruitment Status: Recruiting
• First Posted: April 21, 2021
• Last Update Posted: August 10, 2022
• Sponsor: Conjupro Biotherapeutics, Inc.
• Information provided by (Responsible Party): Conjupro Biotherapeutics, Inc.

Study Description

Brief Summary:

This first-in-human Phase 1 study will be a multicenter, dose-escalating, single-agent study conducted in patients with advanced CD20-associated hematological cancers for which the investigator determines there to be no other higher priority therapies available.

Condition or disease	Intervention/treatment	Phase
CD20 Positive Non Hodgkin Lymphoma	Drug: CPO107	Phase 1; Phase 2

Detailed Description:

This first-in-human Phase 1 study will be a multicenter, dose-escalating, single-agent study conducted in patients with advanced CD20-associated hematological cancers for which the investigator determines there to be no other higher priority therapies available. All patients must have failed at least two prior lines of conventional systemic therapy that must also include an approved CD20 based treatment. All patients will need to have CD20-positive disease, as determined by the expression of CD20 on tumor cells assayed within 6 months prior to study entry.

The study will consist of 2 parts, Part A and Part B. In Part A of the study, dose escalation will proceed according to the guidelines in the Treatment and Dosing section below, following a rule-based design methodology. Two different schedules will be explored to establish the PK profile and thus better inform the selection of the final dosing schedule to be developed. Arm A will explore a continuous weekly dosing schedule and will commence first. Arm B will explore a 3 weekly schedule in which a single dose is administered every 3 weeks. Part B dose expansion of the study will commence, in which a single dosing schedule will be explored in CD20-positive patients. The schedule will be selected based on PK and safety determinants from Study Part A.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 75 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase 1/2, Multicenter, First-In-Human, Dose Escalation and Dose Expansion Study of CPO107 Administered Intravenously to Patients With Advanced CD20-positive Non-Hodgkins Lymphoma
• Actual Study Start Date: December 13, 2021
• Estimated Primary Completion Date: December 15, 2024
• Estimated Study Completion Date: December 15, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: PartA- Arm A; Arm A 1-6 subjects will be enrolled at dose levels of CPO107 at (1, 3, 6, 12, 20 mg/kg). Each subject group will receive multiple cycles of a weekly dose of CPO-107 (1 cycle=21 days=3 treatments).	Drug: CPO107; CD20-CD47 Bispecific Fusion Protein; Other Name: JMT601
Experimental: PartA- Arm B; Arm B will explore a 3 weekly schedule in which a single dose is administered every 3 weeks (1 cycle=21 days=1 treatment). The starting dose for Arm B will be the dose level below the Arm A level that provides an equivalent dose over a 3-week period.	Drug: CPO107; CD20-CD47 Bispecific Fusion Protein; Other Name: JMT601
Experimental: Part B; Part B with either: second or greater relapse OR refractory patients, as defined by not achieving a CR after 2 cycles of a standard first line chemoimmunotherapy regimen or not achieving a CR following 1 cycle of a second line chemotherapy regimen.	Drug: CPO107; CD20-CD47 Bispecific Fusion Protein; Other Name: JMT601

Outcome Measures

Primary Outcome Measures :

1. To determine the recommended single-agent CPO107 RP2D [ Time Frame: through study completion, an average of 1 year ]
   To determine the recommended single-agent CPO107 RP2D and schedule for further exploration in CD20 positive Non-Hodgkins Lymphoma.

Secondary Outcome Measures :

1. Safety assessment-Incidence of treatment-emergent AEs (TEAEs) [ Time Frame: through study completion, an average of 1 year ]
   Safety will be assessed through the analysis of the reported incidence of treatment-emergent AEs (TEAEs) by evaluating adverse events based on laboratory results, vital signs and ECG findings.
2. Pharmacokinetic (PK) [ Time Frame: through study completion, an average of 1 year ]
   The pharmacokinetic of CPO-107 will be assessed by measuring the blood concentration of the drug in the plasma at various timepoints and calculation of parameters, such as Peak Plasma Concentration (Cmax).
3. Expression of anti-drug antibody (ADA) [ Time Frame: through study completion, an average of 1 year ]
   The expression of anti-drug antibodies (ADAs) following administration will be assessed by analysis of serum samples.
4. Efficacy assessment [ Time Frame: through study completion, an average of 1 year ]
   To document any early indication of clinical efficacy.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

The following key inclusion criteria apply to both Part A and Part B:

• Diagnosis of CD20 positive NHL. CD20 assay to have been performed within 6 months prior to protocol entry. Eligible NHL subtypes include Diffuse Large B-Cell Lymphoma (DLBCL, not otherwise specified, NOS), Follicular Lymphoma, Chronic lymphocytic leukemia/small lymphocytic lymphoma, B cell prolymphocytic leukemia and Mantle cell lymphoma.
• Patients with SLL must have received, or not be eligible for, BTK and BCL-2 inhibitor therapy.
• Disease progression or relapse following at least two prior lines of conventional systemic therapy for advanced disease. Dosing regimen must have included a CD20 targeted therapy (for example, RCHOP).
• A clinical indication for treatment must be present for patients with Follicular Lymphoma and Chronic/Small/Prolymphocytic/Mantle B-cell non-Hodgkin lymphoma.
• Having at least one measurable target lesion present and documented by RECIST 1.1.
• Adequate organ function, such as Renal function, Hepatic Function, Cardiovascular, Adequate hematological reserve.
• Complete resolution of all prior toxicities from prior anticancer therapy, defined as having resolved to baseline or to common terminology criteria for adverse events (CTCAE) grade≤1, with the exception of alopecia, or to the levels dictated in the inclusion/exclusion criteria, and a washout period of 5 half-lives of prior small molecule systemic therapy.
• Life expectancy >12 weeks.
• Age: Lower age limit of 18 years.
• ECOG performance status 0 or 1 at screening.
• Ability to understand the nature of this study, comply with protocol requirements, and give written informed consent. For minors, legal guardian willingness to give written informed consent with patient assent, where appropriate.
• Patients of reproductive potential: All female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before study entry.

Exclusion Criteria:

The following key exclusion criteria apply:

• Patients with indolent Follicular Lymphoma or Chronic/Small/Prolymphocytic/Mantle B-cell non-Hodgkin lymphoma in need of immediate cytoreductive therapy are excluded, unless the patient has no remaining treatment choice with potential benefit.
• Patient has participated in any investigational research study and is being screened for participation within a period of 5 half-lives, or 4 weeks of the last dose of the investigational therapy, whichever is longer.
• Patients with history of severe hypersensitivity reactions to anti-CD20 treatment or any components of study drug formulation.
• Presence or recent history within 6 months of arteritis or any systemic clotting disorder, thrombotic or thromboembolic events.
• History or presence of autoimmune conditions; patients who have a medical condition that requires chronic systemic steroid therapy or requires any other form of immunosuppressive medication.
• Patients with a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >480 milliseconds (ms) (CTCAE grade 1) using Fredericia's QT correction formula.
• Active or latent hepatitis B or active hepatitis C or any uncontrolled infection at screening; HIV positive test within 8 weeks of screening.
• Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
• Presence of other active cancers, or history of treatment for invasive cancer ≤3 years.
• Patients who started erythropoietin or granulocyte colony-stimulating factor (G-CSF), pegfilgrastim, or filgrastim ≤4 weeks prior to the first dose of the study drug.
• Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
• Active CNS disease involvement; CNS directed radiation must be completed >8 weeks prior to CPO107 infusion.
• Non-CNS site of radiation must be completed >2 weeks prior to CPO107 infusion.
• Pregnant or nursing (lactating) women
• And others

Contacts and Locations

Contacts

Contact: Kevin Romanko; 609-686-6502; clinicaltrials.gov@cspcus.com

Contact: Audrey Li; 609-356-0210; clinicaltrials.gov@cspcus.com

Locations

United States, California

University of Southern California - Norris Comprehensive Cancer Center; Recruiting

Los Angeles, California, United States, 90033

Contact: Christine Duran 323-865-0371 duran_c@med.usc.edu

Principal Investigator: Zaw Win Myint, MD

Stanford University - Saul A Rosenberg Prof of Lymphoma Stanford Cancer Institute; Recruiting

Stanford, California, United States, 94305

Contact: Lisa Jerden, BA 650-721-4096 ljerden@stanford.edu

Contact: Mariel Rojas, MS 650-723-0530 mlrojas@stanford.edu

Principal Investigator: Ranjana Advani, MD

United States, Colorado

Colorado Blood Cancer Institute; Recruiting

Denver, Colorado, United States, 80218

Contact: Luke Mountjoy, DO 720-754-4800

United States, North Carolina

Novant Health - Charlotte; Recruiting

Charlotte, North Carolina, United States, 28204

Contact: Alan Skarbnik, MD 980-302-6600 azskarbnik@novanthealth.org

Novant Health - Winston-Salem; Recruiting

Winston-Salem, North Carolina, United States, 27103

Contact: Alan Skarbnik, MD 980-302-6600 azskarbnik@novanthealth.org

Sponsors and Collaborators

Conjupro Biotherapeutics, Inc.

Investigators

• Study Director: Steven Novick, MD PhD; Conjupro Biotherapeutics, Inc.

More Information

• Responsible Party: Conjupro Biotherapeutics, Inc.
• ClinicalTrials.gov Identifier: NCT04853329
• Other Study ID Numbers: CPO107-US-1001
• First Posted: April 21, 2021
• Last Update Posted: August 10, 2022
• Last Verified: August 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No
• Plan Description: Undecided

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Conjupro Biotherapeutics, Inc.:

CD20 positive; Non Hodgkin Lymphoma; CD20 CD47; CPO107; Phase 1/2

Additional relevant MeSH terms:

Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases